Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.69 |
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.59 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.59 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.59 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.58 |
| ▸ | CTSB | P07858 | 1/20 | 0.58 |
| ▸ | CTSS | P25774 | 1/20 | 0.58 |
| ▸ | CTSK | P43235 | 1/20 | 0.58 |
| ▸ | CTSC | P53634 | 1/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.58 |
| ▸ | CCR3 | P51677 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19480105 | 0.87 | NPC1 (0.65) | KMT2AUSP2TSHRNPC1RAB9A | |
| SCHEMBL1424917 | 0.86 | KMT2A (0.66) | KMT2AUSP2TSHRNPC1RAB9A | |
| SCHEMBL14590545 | 0.85 | NPSR1 (0.67) | KMT2ANPC1RAB9AMEN1POLB | |
| SCHEMBL4749226 | 0.85 | NPC1 (0.67) | KMT2AUSP2TSHRNPC1RAB9A | |
| SCHEMBL1425012 | 0.85 | KMT2A (0.64) | KMT2AUSP2TSHRNPC1RAB9A | |
| SCHEMBL6539130 | 0.84 | KMT2A (0.67) | KMT2AUSP2TSHRNPC1RAB9A | |
| SCHEMBL19356248 | 0.83 | CRBN (0.56) | KMT2ATSHRMEN1CRBNHDAC4 | |
| SCHEMBL17572986 | 0.83 | KMT2A (0.63) | KMT2ATSHRMEN1POLBCRBN | |
| SCHEMBL14797275 | 0.82 | CRBN (0.55) | KMT2ATSHRMEN1POLBCRBN | |
| SCHEMBL532160 | 0.82 | RAB9A (0.83) | KMT2AUSP2TSHRNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2157082-B1 | NEURITE FORMATION PROMOTER | SENJU PHARMA CO (JP) | 2016-06-08 | — | — | EP | claimed |
| US-8637544-B2 | Neurite formation promoter | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2014-01-28 | — | — | US | claimed |
| EP-1140836-B1 | AMIDE COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2011-03-23 | — | — | EP | claimed |
| US-20100144792-A1 | NEURITE FORMATION PROMOTER | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2010-06-10 | — | — | US | claimed |
| CN-101687795-A | Neuritogenesis promoter | SENJU PHARMA CO | 2010-03-31 | — | — | CN | claimed |
| EP-2157082-A1 | NEURITE FORMATION PROMOTER | Senju Pharmaceutical Co., Ltd. (JP) | 2010-02-24 | — | — | EP | claimed |
| US-6710043-B1 | POSSESS THE POTENTIATION OF THE CHOLINERGIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-23 | — | — | US | claimed |
| US-12637455-B2 | Naphthyridine and pyrido[3,4-c]pyridazine derivatives as GABAA α5 receptor modulators | RICHTER GEDEON NYRT. (HU) | 2026-05-26 | — | — | US | disclosed |
| EP-4126858-B1 | DIHYDRO-2-PYRROLO[3,4-C]PYRIDINE DERIVATIVES AS GABAA A5 RECEPTOR MODULATORS | RICHTER GEDEON NYRT (HU) | 2026-03-18 | — | — | EP | disclosed |
| US-12534458-B2 | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | MERCK SHARP & DOHME LLC (US) | 2026-01-27 | — | — | US | disclosed |
| EP-3856342-B1 | BICYCLIC DERIVATIVES AS GABAA A5 RECEPTOR MODULATORS | RICHTER GEDEON NYRT (HU) | 2025-12-10 | — | — | EP | disclosed |
| US-20250344963-A1 | METHODS FOR ACQUIRING AND ANALYZING NEUROMELANIN-SENSITIVE MRI | UNIV OF OTTAWA INSTITUTE OF MENTAL HEALTH RESEARCH (CA) | 2025-11-13 | — | — | US | disclosed |
| US-20250302913-A1 | LACRIPEP PROMOTES NEUROREGENERATION AND MAINTAINS EPITHELIAL PROGENITOR CELL IDENTITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-10-02 | — | — | US | disclosed |
| WO-2002020016-A1 | AGENT FOR MODULATING EXCITATORY SYNAPTIC TRANSMISSION COMPRISING A COMPOUND HAVING ALPHA α7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATION PROPERTY | FUJISAWA PHARMACEUTICAL CO, LTD (JP) | 2002-03-14 | — | — | WO | disclosed |
| CN-1336917-A | Amide compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-02-20 | — | — | CN | disclosed |
| US-6344358-B1 | ADMINISTERING SOMATOSTATIN RELEASING AGENT TO TREAT BRAIN, PSYCHOLOGICAL AND NERVOUS SYSTEM DISORDERS SUCH AS SCHIZOPHRENIA, AMNESIA, BIPOLAR DISORDER, ALZHEIMER*S DISEASE AND PARKINSON*S DISEASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-05 | — | — | US | disclosed |
| WO-2000072834-A9 | AGENT FOR EXPRESSION OF LONG-TERM POTENTIATION OF SYNAPTIC TRANSMISSION COMPRISING COMPOUND HAVING BRAIN SOMATOSTATIN ACTIVATION PROPERTY | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-12-20 | — | — | WO | disclosed |
| EP-1140836-A1 | AMIDE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000072834-A2 | AGENT FOR EXPRESSION OF LONG-TERM POTENTIATION OF SYNAPTIC TRANSMISSION COMPRISING COMPOUND HAVING BRAIN SOMATOSTATIN ACTIVATION PROPERTY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-12-07 | — | — | WO | disclosed |
| WO-2000042011-A1 | AMIDE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12534458-B2 | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | CHRNA6, CHRNA7, CHRNA5 | KMT2A 3415/4885USP2 3853/4885TSHR 216/4885 |
| US-12637455-B2 | Naphthyridine and pyrido[3,4-c]pyridazine derivatives as GABAA α5 receptor modulators | GABRA5, GABRA1, GABRB1 | KMT2A 4249/4885USP2 4371/4885TSHR 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.